Review





Similar Products

97
Miltenyi Biotec human cd34 hematopoietic stem cells
Human Cd34 Hematopoietic Stem Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd34 hematopoietic stem cells/product/Miltenyi Biotec
Average 97 stars, based on 1 article reviews
human cd34 hematopoietic stem cells - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier

95
Miltenyi Biotec cd34 hematopoietic stem cells rea1164 miltenyi biotec 130 120 515 reafinitytm
Cd34 Hematopoietic Stem Cells Rea1164 Miltenyi Biotec 130 120 515 Reafinitytm, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd34 hematopoietic stem cells rea1164 miltenyi biotec 130 120 515 reafinitytm/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd34 hematopoietic stem cells rea1164 miltenyi biotec 130 120 515 reafinitytm - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

90
Charles River Laboratories human cord blood cd34 + hematopoietic stem and progenitor cells (hspcs)
Human Cord Blood Cd34 + Hematopoietic Stem And Progenitor Cells (Hspcs), supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cord blood cd34 + hematopoietic stem and progenitor cells (hspcs)/product/Charles River Laboratories
Average 90 stars, based on 1 article reviews
human cord blood cd34 + hematopoietic stem and progenitor cells (hspcs) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
StemCyte Inc human cd34+ hematopoietic stem and progenitor cells (hspcs)
Human Cd34+ Hematopoietic Stem And Progenitor Cells (Hspcs), supplied by StemCyte Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd34+ hematopoietic stem and progenitor cells (hspcs)/product/StemCyte Inc
Average 90 stars, based on 1 article reviews
human cd34+ hematopoietic stem and progenitor cells (hspcs) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc human cd34+ hematopoietic stem cells
Human Cd34+ Hematopoietic Stem Cells, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd34+ hematopoietic stem cells/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
human cd34+ hematopoietic stem cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

99
Miltenyi Biotec cd34 hematopoietic stem cells hsc
SMARCA4 deficiency leads to decreased response to anti-PD-1 immunotherapy and impaired immune cell infiltration into tumors in humanized xenograft models. A, Schematic representation detailing the development of the humanized mouse model. Parental and SMARCA4 KO H2122 tumors were introduced into humanized mice at 6 weeks after human <t>CD34</t> + <t>stem</t> <t>cells</t> implantation, with a minimum of 25% huCD45 + cells observed in peripheral blood. Parental xenograft models were subjected to i.p. injections of vehicle or pembrolizumab (250 μg/mouse) every 3 days for 3 weeks, whereas SMARCA4 KO xenograft models were treated in the same manner but for 2 weeks. B, Immunoblots of parental and SMARCA4 KO H2122 cell lysates stained using anti-SMARCA4 and β-actin antibodies. Protein molecular weight markers are in kilodaltons (kDa). C and D, Growth curves of parental H2122 xenograft models ( n = 6 animals per group; C ) or SMARCA4 KO H2122 xenograft models ( n = 5 animals per group; D ) after treatment with isotype control antibodies or anti-PD-1 antibodies were generated. Data points represent the mean ± SEM. *, P < 0.05, two-sided unpaired t test. E–K, The cells isolated from dissociated subcutaneous parental and SMARCA4 KO H2122 xenograft models were analyzed by flow cytometry. E–G, Flow cytometry plot of HLA-DR+ DCs ( E ). The percentage of HLA-DR+ DCs out of CD11b + cells ( F ) and CD103 + cells out of CD3 − CD19 − cells ( G ). H–K, Flow cytometry plot of CD4 + T cells and CD8 + T cells ( H and I ). The percentage of CD4 + T cells ( J ) and CD8 + T cells ( K ) out of CD3 + T cells. Data points represent the mean ± SEM. *, P < 0.05; **, P < 0.01, one-tailed Mann–Whitney test. ns, not significant. ( A, Created with BioRender.com.)
Cd34 Hematopoietic Stem Cells Hsc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd34 hematopoietic stem cells hsc/product/Miltenyi Biotec
Average 99 stars, based on 1 article reviews
cd34 hematopoietic stem cells hsc - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc human peripheral blood cd34+ hematopoietic stem cells
SMARCA4 deficiency leads to decreased response to anti-PD-1 immunotherapy and impaired immune cell infiltration into tumors in humanized xenograft models. A, Schematic representation detailing the development of the humanized mouse model. Parental and SMARCA4 KO H2122 tumors were introduced into humanized mice at 6 weeks after human <t>CD34</t> + <t>stem</t> <t>cells</t> implantation, with a minimum of 25% huCD45 + cells observed in peripheral blood. Parental xenograft models were subjected to i.p. injections of vehicle or pembrolizumab (250 μg/mouse) every 3 days for 3 weeks, whereas SMARCA4 KO xenograft models were treated in the same manner but for 2 weeks. B, Immunoblots of parental and SMARCA4 KO H2122 cell lysates stained using anti-SMARCA4 and β-actin antibodies. Protein molecular weight markers are in kilodaltons (kDa). C and D, Growth curves of parental H2122 xenograft models ( n = 6 animals per group; C ) or SMARCA4 KO H2122 xenograft models ( n = 5 animals per group; D ) after treatment with isotype control antibodies or anti-PD-1 antibodies were generated. Data points represent the mean ± SEM. *, P < 0.05, two-sided unpaired t test. E–K, The cells isolated from dissociated subcutaneous parental and SMARCA4 KO H2122 xenograft models were analyzed by flow cytometry. E–G, Flow cytometry plot of HLA-DR+ DCs ( E ). The percentage of HLA-DR+ DCs out of CD11b + cells ( F ) and CD103 + cells out of CD3 − CD19 − cells ( G ). H–K, Flow cytometry plot of CD4 + T cells and CD8 + T cells ( H and I ). The percentage of CD4 + T cells ( J ) and CD8 + T cells ( K ) out of CD3 + T cells. Data points represent the mean ± SEM. *, P < 0.05; **, P < 0.01, one-tailed Mann–Whitney test. ns, not significant. ( A, Created with BioRender.com.)
Human Peripheral Blood Cd34+ Hematopoietic Stem Cells, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human peripheral blood cd34+ hematopoietic stem cells/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
human peripheral blood cd34+ hematopoietic stem cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Hemacare Inc human mobilized peripheral blood (mpb) cd34+ hematopoietic stem and progenitor cells (hspcs)
SMARCA4 deficiency leads to decreased response to anti-PD-1 immunotherapy and impaired immune cell infiltration into tumors in humanized xenograft models. A, Schematic representation detailing the development of the humanized mouse model. Parental and SMARCA4 KO H2122 tumors were introduced into humanized mice at 6 weeks after human <t>CD34</t> + <t>stem</t> <t>cells</t> implantation, with a minimum of 25% huCD45 + cells observed in peripheral blood. Parental xenograft models were subjected to i.p. injections of vehicle or pembrolizumab (250 μg/mouse) every 3 days for 3 weeks, whereas SMARCA4 KO xenograft models were treated in the same manner but for 2 weeks. B, Immunoblots of parental and SMARCA4 KO H2122 cell lysates stained using anti-SMARCA4 and β-actin antibodies. Protein molecular weight markers are in kilodaltons (kDa). C and D, Growth curves of parental H2122 xenograft models ( n = 6 animals per group; C ) or SMARCA4 KO H2122 xenograft models ( n = 5 animals per group; D ) after treatment with isotype control antibodies or anti-PD-1 antibodies were generated. Data points represent the mean ± SEM. *, P < 0.05, two-sided unpaired t test. E–K, The cells isolated from dissociated subcutaneous parental and SMARCA4 KO H2122 xenograft models were analyzed by flow cytometry. E–G, Flow cytometry plot of HLA-DR+ DCs ( E ). The percentage of HLA-DR+ DCs out of CD11b + cells ( F ) and CD103 + cells out of CD3 − CD19 − cells ( G ). H–K, Flow cytometry plot of CD4 + T cells and CD8 + T cells ( H and I ). The percentage of CD4 + T cells ( J ) and CD8 + T cells ( K ) out of CD3 + T cells. Data points represent the mean ± SEM. *, P < 0.05; **, P < 0.01, one-tailed Mann–Whitney test. ns, not significant. ( A, Created with BioRender.com.)
Human Mobilized Peripheral Blood (Mpb) Cd34+ Hematopoietic Stem And Progenitor Cells (Hspcs), supplied by Hemacare Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human mobilized peripheral blood (mpb) cd34+ hematopoietic stem and progenitor cells (hspcs)/product/Hemacare Inc
Average 90 stars, based on 1 article reviews
human mobilized peripheral blood (mpb) cd34+ hematopoietic stem and progenitor cells (hspcs) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
AllCells LLC human mobilized peripheral blood (mpb) cd34+ hematopoietic stem and progenitor cells (hspcs)
SMARCA4 deficiency leads to decreased response to anti-PD-1 immunotherapy and impaired immune cell infiltration into tumors in humanized xenograft models. A, Schematic representation detailing the development of the humanized mouse model. Parental and SMARCA4 KO H2122 tumors were introduced into humanized mice at 6 weeks after human <t>CD34</t> + <t>stem</t> <t>cells</t> implantation, with a minimum of 25% huCD45 + cells observed in peripheral blood. Parental xenograft models were subjected to i.p. injections of vehicle or pembrolizumab (250 μg/mouse) every 3 days for 3 weeks, whereas SMARCA4 KO xenograft models were treated in the same manner but for 2 weeks. B, Immunoblots of parental and SMARCA4 KO H2122 cell lysates stained using anti-SMARCA4 and β-actin antibodies. Protein molecular weight markers are in kilodaltons (kDa). C and D, Growth curves of parental H2122 xenograft models ( n = 6 animals per group; C ) or SMARCA4 KO H2122 xenograft models ( n = 5 animals per group; D ) after treatment with isotype control antibodies or anti-PD-1 antibodies were generated. Data points represent the mean ± SEM. *, P < 0.05, two-sided unpaired t test. E–K, The cells isolated from dissociated subcutaneous parental and SMARCA4 KO H2122 xenograft models were analyzed by flow cytometry. E–G, Flow cytometry plot of HLA-DR+ DCs ( E ). The percentage of HLA-DR+ DCs out of CD11b + cells ( F ) and CD103 + cells out of CD3 − CD19 − cells ( G ). H–K, Flow cytometry plot of CD4 + T cells and CD8 + T cells ( H and I ). The percentage of CD4 + T cells ( J ) and CD8 + T cells ( K ) out of CD3 + T cells. Data points represent the mean ± SEM. *, P < 0.05; **, P < 0.01, one-tailed Mann–Whitney test. ns, not significant. ( A, Created with BioRender.com.)
Human Mobilized Peripheral Blood (Mpb) Cd34+ Hematopoietic Stem And Progenitor Cells (Hspcs), supplied by AllCells LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human mobilized peripheral blood (mpb) cd34+ hematopoietic stem and progenitor cells (hspcs)/product/AllCells LLC
Average 90 stars, based on 1 article reviews
human mobilized peripheral blood (mpb) cd34+ hematopoietic stem and progenitor cells (hspcs) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


SMARCA4 deficiency leads to decreased response to anti-PD-1 immunotherapy and impaired immune cell infiltration into tumors in humanized xenograft models. A, Schematic representation detailing the development of the humanized mouse model. Parental and SMARCA4 KO H2122 tumors were introduced into humanized mice at 6 weeks after human CD34 + stem cells implantation, with a minimum of 25% huCD45 + cells observed in peripheral blood. Parental xenograft models were subjected to i.p. injections of vehicle or pembrolizumab (250 μg/mouse) every 3 days for 3 weeks, whereas SMARCA4 KO xenograft models were treated in the same manner but for 2 weeks. B, Immunoblots of parental and SMARCA4 KO H2122 cell lysates stained using anti-SMARCA4 and β-actin antibodies. Protein molecular weight markers are in kilodaltons (kDa). C and D, Growth curves of parental H2122 xenograft models ( n = 6 animals per group; C ) or SMARCA4 KO H2122 xenograft models ( n = 5 animals per group; D ) after treatment with isotype control antibodies or anti-PD-1 antibodies were generated. Data points represent the mean ± SEM. *, P < 0.05, two-sided unpaired t test. E–K, The cells isolated from dissociated subcutaneous parental and SMARCA4 KO H2122 xenograft models were analyzed by flow cytometry. E–G, Flow cytometry plot of HLA-DR+ DCs ( E ). The percentage of HLA-DR+ DCs out of CD11b + cells ( F ) and CD103 + cells out of CD3 − CD19 − cells ( G ). H–K, Flow cytometry plot of CD4 + T cells and CD8 + T cells ( H and I ). The percentage of CD4 + T cells ( J ) and CD8 + T cells ( K ) out of CD3 + T cells. Data points represent the mean ± SEM. *, P < 0.05; **, P < 0.01, one-tailed Mann–Whitney test. ns, not significant. ( A, Created with BioRender.com.)

Journal: Cancer Research

Article Title: Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy

doi: 10.1158/0008-5472.CAN-24-2054

Figure Lengend Snippet: SMARCA4 deficiency leads to decreased response to anti-PD-1 immunotherapy and impaired immune cell infiltration into tumors in humanized xenograft models. A, Schematic representation detailing the development of the humanized mouse model. Parental and SMARCA4 KO H2122 tumors were introduced into humanized mice at 6 weeks after human CD34 + stem cells implantation, with a minimum of 25% huCD45 + cells observed in peripheral blood. Parental xenograft models were subjected to i.p. injections of vehicle or pembrolizumab (250 μg/mouse) every 3 days for 3 weeks, whereas SMARCA4 KO xenograft models were treated in the same manner but for 2 weeks. B, Immunoblots of parental and SMARCA4 KO H2122 cell lysates stained using anti-SMARCA4 and β-actin antibodies. Protein molecular weight markers are in kilodaltons (kDa). C and D, Growth curves of parental H2122 xenograft models ( n = 6 animals per group; C ) or SMARCA4 KO H2122 xenograft models ( n = 5 animals per group; D ) after treatment with isotype control antibodies or anti-PD-1 antibodies were generated. Data points represent the mean ± SEM. *, P < 0.05, two-sided unpaired t test. E–K, The cells isolated from dissociated subcutaneous parental and SMARCA4 KO H2122 xenograft models were analyzed by flow cytometry. E–G, Flow cytometry plot of HLA-DR+ DCs ( E ). The percentage of HLA-DR+ DCs out of CD11b + cells ( F ) and CD103 + cells out of CD3 − CD19 − cells ( G ). H–K, Flow cytometry plot of CD4 + T cells and CD8 + T cells ( H and I ). The percentage of CD4 + T cells ( J ) and CD8 + T cells ( K ) out of CD3 + T cells. Data points represent the mean ± SEM. *, P < 0.05; **, P < 0.01, one-tailed Mann–Whitney test. ns, not significant. ( A, Created with BioRender.com.)

Article Snippet: After mononuclear cells were separated from human umbilical cord blood, CD34 + hematopoietic stem cells (HSC) were isolated using CD34 + MicroBead Kit (Miltenyi Biotec, cat. #130-046-702).

Techniques: Western Blot, Staining, Molecular Weight, Control, Generated, Isolation, Flow Cytometry, One-tailed Test, MANN-WHITNEY